CETP Inhibition in CVD Prevention: an Actual Appraisal

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

(2015) Stephen J. Nicholls et al.   AMERICAN HEART JOURNAL

Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib

(2015) Stephen J. Nicholls et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial

(2015) G Kees Hovingh et al.   LANCET

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

(2015) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial

(2014) Kausik K. Ray et al.   EUROPEAN HEART JOURNAL

Evaluation of Lipids, Drug Concentration, and Safety Parameters Following Cessation of Treatment With the Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients With or at High Risk for Coronary Heart Disease

(2013) Antonio M. Gotto et al.   AMERICAN JOURNAL OF CARDIOLOGY

Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study

(2013) Sander J. Robins et al.   ATHEROSCLEROSIS

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

(2012) Thomas F. Lüscher et al.   EUROPEAN HEART JOURNAL

Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects

(2012) Trine Holm Johannsen et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study

(2012) Benjamin F Voight et al.   LANCET

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome

(2012) Gregory G. Schwartz et al.   NEW ENGLAND JOURNAL OF MEDICINE

High plasma cholesteryl ester transfer but not CETP mass predicts incident cardiovascular disease: A nested case–control study

(2011) Paul J.W.H. Kappelle et al.   ATHEROSCLEROSIS

Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A 1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2011) Philip J. Barter et al.   CIRCULATION

Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol

(2011) Stephen J. Nicholls et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

(2011) Christian Besler et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

(2011) Zahi A Fayad et al.   LANCET

On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)

(2010) Amit V. Khera et al.   AMERICAN JOURNAL OF CARDIOLOGY

Restoration of High-Density Lipoprotein Levels by Cholesteryl Ester Transfer Protein Expression in Scavenger Receptor Class B Type I (SR-BI) Knockout Mice Does Not Normalize Pathologies Associated With SR-BI Deficiency

(2010) Reeni B. Hildebrand et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Cholesteryl Ester Transfer Protein and Mortality in Patients Undergoing Coronary Angiography

(2010) Andreas Ritsch et al.   CIRCULATION

Cholesteryl ester transfer protein in patients with coronary heart disease

(2010) Kristina Duwensee et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

(2010) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Pharmacology and Off-Target Effects of Some Cholesterol Ester Transfer Protein Inhibitors

(2009) Menno Vergeer et al.   AMERICAN JOURNAL OF CARDIOLOGY

Lessons Learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial

(2009) Philip Barter   AMERICAN JOURNAL OF CARDIOLOGY

Association of Circulating Cholesteryl Ester Transfer Protein Activity With Incidence of Cardiovascular Disease in the Community

(2009) Ramachandran S. Vasan et al.   CIRCULATION

Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis

(2008) Stephen J. Nicholls et al.   CIRCULATION

Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk

(2008) Alexander Thompson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION